|

Neoadjuvant chemo-immunotherapy Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • University Hospital, Antwerp1
  • Sun Yat-sen University1

Indications

  • Lung Cancer2
  • Cancer2
  • Pleural Epithelioid Mesothelioma1
  • Mesothelioma; Pleura1
  • Stage III Non-small Cell Lung Cancer1

Other2 trials

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
Phase 1/2
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.